Michael J Cunningham, Hailey A Bock, Inis C Serrano, Benjamin Bechand, D J Vidyadhara, Emma M Bonniwell, David Lankri, Priscilla Duggan, Antonina L Nazarova, Andrew B Cao, Maggie M Calkins, Prashant Khirsariya, Christopher Hwu, Vsevolod Katritch, Sreeganga S Chandra, John D McCorvy, Dalibor Sames
Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. Ariadne has been tested in humans including clinical trials at Bristol-Myers Company that indicate a lack of hallucinogenic effects and remarkable therapeutic effects, such as rapid remission of psychotic symptoms in schizophrenics, relaxation in catatonics, complete remission of symptoms in Parkinson's disease (PD), and improved cognition in geriatric subjects...
December 15, 2022: ACS Chemical Neuroscience